TOKYO -- Japanese manufacturers of diagnostic tests for diabetes and other illnesses are ramping up operations in the rest of Asia, as they hope to catch up with global players by tapping into emerging markets.
In Southeast Asia, CMIC Holdings is launching a diabetes diagnostics business geared toward the affluent. The company recently received regulatory approval for its diabetes tests in the Philippines and Vietnam. CMIC will offer a service that can predict kidney disease, based on artificial intelligence that analyzes data collected at hospitals using its tests.
